Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods

US8409607B2 · kind B2 · utility

Assignee

• Allergan, Inc. · US

Inventors

• Patrick M. Hughes · Aliso Viejo, US
• Thomas C. Malone · Irvine, US
• Gerald W. De Vries · Laguna Hills, US
• Jeffery L. Edelman · Irvine, US
• Joan-En Chang-Lin · Tustin, US
• Jane-Guo Shiah · Irvine, US
• Thierry Nivaggioli · San Francisco, US

Key dates

• Filing date: Feb 11, 2008
• Grant date: Apr 2, 2013
• Expiry date: Mar 13, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T428/2985
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.